IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease

Gengfu Dong; Chatick Moparthy; Trace Thome; Kyoungrae Kim; Feng Yue; Terence E Ryan

doi:10.1016/j.jacbts.2022.12.006

IGF-1 Therapy Improves Muscle Size and Function in Experimental Peripheral Arterial Disease

JACC Basic Transl Sci. 2023 Mar 8;8(6):702-719. doi: 10.1016/j.jacbts.2022.12.006. eCollection 2023 Jun.

Authors

Gengfu Dong¹, Chatick Moparthy¹, Trace Thome¹, Kyoungrae Kim¹, Feng Yue^{2

3}, Terence E Ryan^{1

4

3}

Affiliations

¹ Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida, USA.
² Department of Animal Sciences, University of Florida, Gainesville, Florida, USA.
³ Myology Institute, University of Florida, Gainesville, Florida, USA.
⁴ Center for Exercise Science, University of Florida, Gainesville, Florida, USA.

Abstract

Lower-extremity peripheral arterial disease (PAD) has increased in prevalence, yet therapeutic development has remained stagnant. Skeletal muscle health and function has been strongly linked to quality of life and medical outcomes in patients with PAD. Using a rodent model of PAD, this study demonstrates that treatment of the ischemic limb with insulin-like growth factor (IGF)-1 significantly increases muscle size and strength without improving limb hemodynamics. Interestingly, the effect size of IGF1 therapy was larger in female mice than in male mice, highlighting the need to carefully examine sex-dependent effects in experimental PAD therapies.

Keywords: chronic limb threatening ischemia; gene therapy; regeneration; skeletal muscle.

Abstract

Grants and funding